Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novartis
Biotech
Novartis only wanted pelabresib, but MorphoSys had other ideas
A peek into the deal negotiations reveals that the Swiss pharma would have been happier if it could have walked away with one specific asset.
James Waldron
Apr 12, 2024 8:53am
Novartis pays $150M for Arvinas' prostate tumor protein degrader
Apr 11, 2024 8:04am
Top 10 pharma R&D budgets in 2023
Mar 18, 2024 5:00am
Novartis hits the cGAS, taking up option to buy IFM unit
Mar 13, 2024 9:01am
Novartis lines up another potential indication for BTK inhibitor
Mar 9, 2024 12:00pm
Cytokinetics not in sale process, CEO says
Feb 28, 2024 11:25am